Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition
复制标题
DOI：
10.1097/mpg.0000000000001872
复制
发表时间：
2018-03-01
影响因子：
2.9
通讯作者：
Fischler, Bjorn
中科院分区：
文献类型：
--
作者：
Indolfi, Giuseppe;Hierro, Loreto;Fischler, Bjorn
目的：2017年，欧洲药品管理局和食品和药物管理局批准使用来地帕韦/索莫布韦和索莫布韦和利巴韦林的固定剂量组合治疗青少年(12-17岁或体重35公斤)慢性丙型肝炎病毒(HCV)基因1、4、5和6以及基因2和3感染。尽管针对年幼儿童的直接作用抗病毒药物的试验仍在进行中，但在美国和欧洲，针对这些儿童的唯一可用的治疗方法
Objectives: In 2017, the European Medicines Agency and the Food and Drug Administration approved the use of the fixed-dose combination of ledipasvir/sofosbuvir and of the combination of sofosbuvir and ribavirin for treatment of adolescents (12-17 years or weighing > 35 kg) with chronic hepatitis C virus (HCV) genotype 1, 4, 5, and 6 and genotype 2 and 3 infections, respectively. Although trials with direct-acting antivirals are ongoing for younger children, the only available treatment in the United States and Europe for those